ESTRO 2024 - Abstract Book

S677

Clinical - Breast

ESTRO 2024

(N=157)

(4.6)

(5.6)

(1.6)

94.4)

ER-,PR-

83

511

28

27

(N=649)

(13.3)

(51.4)

(2.4)

(2.3)

Missing (N=254)

84

112

47

11

(13.4)

(11.3)

(4.0)

(0.9)

ER = Oestrogen Receptor, PR= Progesterone Receptor, PR-unknown or ER-unknown- status of receptor unknown

*All p-values have been calculated without taking into consideration the missing/unknown values for each variable

Conclusion:

The administration of systemic therapy, especially endocrine therapy with or without chemotherapy, was associated with lower local recurrence rates, based on a model adjusted for baseline and treatment factors. The observed frequencies of all other breast events were higher for those who had adjuvant chemotherapy regardless, which can be explained by risk factors at randomisation.

Keywords: breast cancer, recurrence, chemotherapy

References:

Poortmans PM, Weltens C, Fortpied C, Kirkove C, Peignaux-Casasnovas K, Budach V, van der Leij F, Vonk E, Weidner N, Rivera S, van Tienhoven G, Fourquet A, Noel G, Valli M, Guckenberger M, Koiter E, Racadot S, Abdah-Bortnyak R, Van Limbergen EF, Engelen A, De Brouwer P, Struikmans H, Bartelink H; European Organisation for Research and Treatment of Cancer Radiation Oncology and Breast Cancer Groups. Internal mammary and medial supraclavicular lymph node chain irradiation in stage I-III breast cancer (EORTC 22922/10925): 15-year results of a randomised, phase 3 trial. Lancet Oncol. 2020 ;21(12):1602-1610.

2776

Digital Poster

Radiotherapy and novel antibody-drug conjugates in breast cancer patients

Edy Ippolito 1,2 , Martina Benincasa 2 , Sonia Silipigni 1 , Jessica Infante 2 , Marco Donato 3 , Francesco Pantano 4,3 , Michele Fiore 1,2 , Carlo Greco 1,2 , Elisabetta Molfese 1 , Alessia Di Donato 1 , Cecilia Sciommari 1 , Alessia Carnevale 1 , Giuseppe Tonini 4,3 , Sara Ramella 1,2